Max is a Partner in Trinity’s Value, Access and Pricing practice. His experience as a global life sciences strategy consultant spans all stages of product development and a wide range of therapeutic areas, including oncology, inflammatory conditions, rare diseases and cell and gene therapies.  

Prior to joining Trinity, Max’s engagement work at CBPartners targeted a variety of commercial business issues related to pricing, access and value with a focus in the U.S., Europe, Japan and other global markets. Max is devoted to delivering innovative and impactful commercial strategy recommendations to biopharmaceutical manufacturers working to navigate the evolving global payer marketplace.  

Max previously worked in the strategy consulting division of Leerink Partners and holds a BS in Biomedical Engineering from Johns Hopkins University.